Tempus AI

We’re excited to announce that our PurIST℠ algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurIST℠ PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms. Learn more: https://tempus.co/3zx5QmZ

We’re excited to announce that the Centers for Medicare & Medicaid Services has granted Advanced Diagnostic Laboratory Test (ADLT) status for our xT CDx test. xT CDx is the first FDA-approved next-generation sequencing assay to perform matched normal sequence analysis to provide tumor mutation profiling for patients with solid organ neoplasms. Learn more: https://tempus.co/3L9vnVO

As #PrideMonth comes to a close, we want to extend a massive thank you to our Pride Employee Resource Group that executed a month full of inspiring, thought-provoking, and fun activities so we could celebrate our LGBTQIA employees and allies. We’re grateful for this dedicated month to honor the history, culture, and contributions of LGBTQIA individuals.

We’re thrilled to announce that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our ECG-AF device that uses AI to help identify patients who may be at an increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software” and paves the way for physicians to use this innovative algorithm in the care of their patients. Read more: https://tempus.co/3RFqKqj

We’re excited to be partnering with United Therapeutics Corporation to develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension (PH). Together with UT, we plan to implement this prospective clinical study at up to 60 centers to evaluate the clinical impact of this technology and gain new insights into the detection and diagnosis of PH. Read more: https://tempus.co/3XFC0a4

Join us on Tuesday, July 9th at 1:00 p.m. CT for an upcoming #webinar, “Harnessing the Power of AI: Optimizing Workflows & Enhancing Testing Across the Cancer Care Continuum.” Tempus speakers, Ezra Cohen, MD, FASCO, Kate Sasser, PhD, and Halla Nimeiri, MD, will discuss the latest advancements in our AI & technology, as well as our recent expansion into the MRD and monitoring space, which are helping to streamline efficiencies in clinical practices and research processes. Register here: https://tempus.co/4ctgf1f

An analysis of 15,000 de-identified Tempus nP PGx patient records, recently published in Molecular Psychiatry, revealed that 65% of patients had CYP2D6 and CYP2C19 phenotypes actionable for medication prescribing. More than half of the top 25 most frequently prescribed medications in psychiatry are metabolized by CYP2D6 and CYP2C19, emphasizing the importance of these findings. Access the full manuscript here: https://tempus.co/3VMYjZW

👩⚕️ 2000+ connected healthcare providers.  🔬 7.7M+ de-identified records for research.  🤖 60 AI algorithms deployed clinically. ⬇️ It’s why Tempus AI is leading the way in data-driven precision medicine. #NasdaqListed

🎉 Welcome to the Nasdaq family, Tempus AI! 🎉 🤖 $TEM harnesses the power of data and AI to drive precision medicine forward. Now they’re officially #NasdaqListed!

Thank you to all of our patients and physician and research partners for your collective commitment to our mission of improving patient outcomes. This is just the beginning.